<code id='8DCFB7C255'></code><style id='8DCFB7C255'></style>
    • <acronym id='8DCFB7C255'></acronym>
      <center id='8DCFB7C255'><center id='8DCFB7C255'><tfoot id='8DCFB7C255'></tfoot></center><abbr id='8DCFB7C255'><dir id='8DCFB7C255'><tfoot id='8DCFB7C255'></tfoot><noframes id='8DCFB7C255'>

    • <optgroup id='8DCFB7C255'><strike id='8DCFB7C255'><sup id='8DCFB7C255'></sup></strike><code id='8DCFB7C255'></code></optgroup>
        1. <b id='8DCFB7C255'><label id='8DCFB7C255'><select id='8DCFB7C255'><dt id='8DCFB7C255'><span id='8DCFB7C255'></span></dt></select></label></b><u id='8DCFB7C255'></u>
          <i id='8DCFB7C255'><strike id='8DCFB7C255'><tt id='8DCFB7C255'><pre id='8DCFB7C255'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:5225

          When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

          advertisement

          For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Prescription digital therapeutics are key to pharma’s future
          Prescription digital therapeutics are key to pharma’s future

          AdobeFiveyearsfromnow,whenpatientswalkintoadoctor’sofficepresentingsymptomsofalmostanyconditionyouca

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          What affirmative action's end means to a medical student

          LaShyraNolenisthefirstinherfamilytogetabachelorsofsciencedegreeandtoattendmedicalschool.CourtesyGret